2025GEW x Guoqian Venture Capital x Suzhou Angel Master Fund
In the era of innovation driven development, every entrepreneurial dream contains infinite possibilities to change the world. In 2025, the 19th Entrepreneurship Week and Global Entrepreneurship Week China Station (GEW) arrived as scheduled, bringing together entrepreneurs and investors from all over the world to initiate a dialogue about innovation and the future. As one of the most influential events in the global entrepreneurship field, 2025GEW (Global Entrepreneurship Week China Station) collaborates with DoerLink Relay Program to hold a special roadshow, jointly organized by United Nations Millennium Venture Capital, Suzhou Angel Mother Fund, and Relay Science and Technology Innovation, to "find" capital for projects and jointly create the 2025GEW annual roadshow feast!
This roadshow will invite 7 technology innovation enterprises and projects, 60+professional investors, and efficiently carry out investment and financing docking with university achievements transformation and exchange roadshows. The atmosphere on site is very lively, with continuous Q&A and frequent interaction between project spokespersons, judges, and investors, and enthusiastic response!
Roadshow project style (ranked in no particular order)
01.Yu Lu Qianxing
Project Introduction：
Suzhou Yulu Qianxing Biotechnology Co., Ltd. (Divamiss Inc.) has created a unique multi-scale molecular dynamics simulation platform and innovative drug early research decision-making AI platform, aiming to more accurately understand the dynamic interactions and mechanisms between drug molecules and targets, rationally design drugs, predict drug efficacy and drug properties, break through the bottleneck of traditional drug discovery, and provide a Hits to PCC integrated research and development platform for various types of drugs such as small molecules, peptides, and macromolecules. The company has been awarded the Suzhou Industrial Park Science and Technology Leading Project, Suzhou City level Gusu Leading Talent Project, National High tech Enterprise, and its core technology has been recommended by Professor Roald Hoffmann, a Nobel Prize winner in Chemistry. The company is headquartered in Suzhou, with a computing center in Beijing and BD cooperation centers in Singapore and Japan. Currently, it has collaborated with over 40 domestic and foreign biopharmaceutical companies to promote more than 70 new drug research and development pipelines.
The core team of Ruiyi Xulian has returned to China from famous foreign hospitals and industries to start their own businesses, with profound industry accumulation. The company continues to focus on the core foundational technologies of brain computer interfaces, including implantable flexible sensors, packaging materials and processes, new materials, wireless energy transmission, chips, and AI algorithms, forming the core technology supply capability of implantable brain computer interfaces. Breakthrough bottleneck technology and achieve self-produced and localized production of all core components and technologies. The company is committed to applying implantable high-density closed-loop brain computer interface technology to solve brain diseases that are difficult to solve in conventional clinical diagnosis and treatment, and is expected to break through the bottleneck and ceiling of neural regulation in the treatment of epilepsy and depression. The current core product of the company, the "Implantable Spinal Interface," has been designed and finalized, and its core performance is at the forefront of the world. It is expected to enter the clinical trial stage in 2026. Currently, no product in the world has entered formal clinical trials. The company actively faces the future, building a basic operating system BOS for brain computer interfaces, integrating with artificial intelligence, and laying the foundation for the future industry of human body enhancement and human-machine integration brain computer interfaces.
02.Watt Medical
Project Introduction：Watt Medical is committed to integrating intelligent temperature control systems with precise energy output control technology, differentiated needle body design and coating technology, and AI intelligent system development. It has developed core technology products such as microwave ablation devices and microwave ablation needles, which can penetrate deeper tissues and cause minimal trauma to patients during treatment, with short recovery time and suitable for the treatment of various types of tumors. By utilizing intelligent temperature control and precise energy control systems, combined with differentiated needle body design, and combining AI with actual physical parameter feedback, the existing microwave ablation has been upgraded from empirical ablation to precise ablation with an accuracy of 90%, breaking through the previous bottleneck that relied solely on doctor experience and solving the biggest clinical pain point at present.
03.Akasho Sheng
Project Introduction：
Suzhou Akaso Biotechnology Co., Ltd. is a technology innovation enterprise that provides core raw materials and overall solutions for global biomedical customers. It is committed to the research and production of core raw materials in the upstream fields of biomedicine and in vitro diagnostics. Akaso Biotech aims to build a high-performance microsphere intelligent chip factory, combining the advantages of molecular biology, immunology, biochemistry, polymer nanomaterials, and microfluidic chip technology to establish multiple technology platforms such as chromatography fillers, immunomagnetic beads, and medical beauty microspheres. The product is widely used in fields such as life sciences, in vitro diagnostics, and biomedicine, providing customers with one-stop procurement services.
04.Shangji Biotechnology
Shangji Biotechnology focuses on innovative research and development in gene and cell therapy, developing the underlying core technologies of synthetic biology and conducting multiple research and development directions in innovative diagnostic technologies and pharmaceutical treatment plans based on this foundation. The innovative fully automated high-throughput gene synthesis technology Oli GO independently developed by the team is an international first, which will break through the current bottleneck of gene synthesis technology, achieve a flux level of over one million, make gene synthesis as simple and fast as PCR, and reduce the cost to one percent to one thousandth of the current level. Shangji Biotechnology's existing OASIS automated gene synthesis workstation has completed technical research and development and entered the final parameter debugging stage for the prototype; And important milestones such as equipment appearance design and software development have been completed. This product will automate the current technology intensive and labor-intensive gene synthesis industry, greatly increasing production efficiency by 5-10 times. Gene synthesis is based solely on sequence requirements information and does not require templates. Functional double stranded DNA can be artificially synthesized in vitro, allowing for the design and synthesis of genes that are difficult to obtain in nature, as well as genomes that include complete metabolic pathways. Gene synthesis is located at the top of the life science industry chain, providing key technical and product support for the synthetic biology industry. Downstream application directions of gene synthesis include the production of DNA vaccines, gene therapy vectors, protein, peptide, antibody and other biopharmaceutical research and development.
05.Stone Finger Health
Project Introduction：
The company was established in June 2019 and is the first (internationally leading) AI bio twin platform in China that contains multi-scale and multi physics fields with biological characteristics. It assists medical device and drug companies in product research and development design, production molding, registration and market promotion without clinical or animal experiments, and evaluation and registration of simulation reports by drug regulatory authorities; Assist the clinical department director in scientific research work; Assist in teaching and training new products, and create AI biological twin models.
06.Vision Medical
Project Introduction：
Shitong Medical was established in May 2022, focusing on the research and development, design, manufacturing, sales, and after-sales service of natural cavity surgical robots. Its main products include digestive endoscopic surgical systems that replace endoscopic surgery, gynecological endoscopic surgical systems that replace traditional surgery, and endoscopic surgical systems that replace craniotomy surgery. The design of flexible robotic arms can adapt to complex anatomical structures, reduce tissue interference, have a small instrument arm diameter, and operate flexibly. Independently developing core technology modules to reduce manufacturing costs, the price of robotic arm consumables is comparable to traditional surgical consumables, suitable for existing medical environments, and easy to sink to second - and third tier city hospitals. Multiple rounds of financing have been completed, including A+and Pre-A+rounds, with investors including Suzhou Angel Fund, Leading Venture Capital, and Bilibili Star Venture Capital. Shitong Medical is committed to becoming a technology pioneer and market leader in the field of flexible surgical robots for natural cavities worldwide. Through platform technology, we aim to create flexible, miniaturized, and low-cost surgical robots, promote inclusive healthcare, and cover clinical departments such as gynecology, gastroenterology, neurosurgery, and general surgery, gradually achieving full coverage of clinical departments.
07.Ruiyi Xulian
Project Introduction：
The core team of Ruiyi Xulian has returned to China from famous foreign hospitals and industries to start their own businesses, with profound industry accumulation. The company continues to focus on the core foundational technologies of brain computer interfaces, including implantable flexible sensors, packaging materials and processes, new materials, wireless energy transmission, chips, and AI algorithms, forming the core technology supply capability of implantable brain computer interfaces. Breakthrough bottleneck technology and achieve self-produced and localized production of all core components and technologies. The company is committed to applying implantable high-density closed-loop brain computer interface technology to solve brain diseases that are difficult to solve in conventional clinical diagnosis and treatment, and is expected to break through the bottleneck and ceiling of neural regulation in the treatment of epilepsy and depression. The current core product of the company, the "Implantable Spinal Interface," has been designed and finalized, and its core performance is at the forefront of the world. It is expected to enter the clinical trial stage in 2026. Currently, no product in the world has entered formal clinical trials. The company actively faces the future, building a basic operating system BOS for brain computer interfaces, integrating with artificial intelligence, and laying the foundation for the future industry of human body enhancement and human-machine integration brain computer interfaces.
Review of exciting moments on site
Guoqian is honored to join hands with ecological partners, excellent project teams, and investor partners to exchange ideas and achieve win-win cooperation at GEW, the most influential event in the global entrepreneurship field. Guoqian will continue to provide efficient financing connections for entrepreneurs and assist in the growth of entrepreneurial projects.